.jpg "Iovance Biotherapeutics Inc (NASDAQ: IOVA)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Iovance Biotherapeutics Inc (NASDAQ: IOVA), Synergy Pharmaceuticals Inc (NASDAQ: SGYP) and Histogenics (NASDAQ: HSGX) with bullish sentiments.
Iovance Biotherapeutics Inc (NASDAQ: IOVA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA), with a price target of $22. The company’s shares closed yesterday at $14.85.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.8% and a 34.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Mateon Therapeutics Inc.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is Strong Buy and the average price target is $24.75, representing a 66.7% upside.
In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $22 price target.
See today’s analyst top recommended stocks >>
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP), with a price target of $7. The company’s shares closed yesterday at $1.63, close to its 52-week low of $1.43.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -6.6% and a 37.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Synergy Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $9.33.
Histogenics (NASDAQ: HSGX)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Histogenics (NASDAQ: HSGX) today and set a price target of $3.50. The company’s shares closed yesterday at $2.49.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.1% and a 37.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Histogenics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
